

Electrochemotherapy for colorectal cancer using endoscopic electroporation: a phase 1 clinical study



Authors

Hanne Falk Hansen¹, Michael Bourke², Trine Stigaard³, James Clover², Martin Buckley⁴, Micheal O'Riordain⁵, Des C. Winter⁶, Helle Hjorth Johannesen⁷, Rasmus Hvass Hansen⁷, Hanne Heebøll⁷, Patrick Forde², Henrik Loft Jakobsen³, Ole Larsen⁸, Jacob Rosenberg^{3,10}, Declan Soden², Julie Gehl^{1,9,10}

Institutions

- 1 Center for experimental drug and gene electrotransfer (C*EDGE), Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark
- 2 Cork Cancer Research Centre, University College Cork, Ireland
- 3 Gastro Unit, Department of Surgical Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark
- 4 Gastroenterology Department, Mercy University Hospital, Cork, Ireland
- 5 Department of Surgery, Mercy University Hospital, Cork, Ireland
- 6 Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland
- 7 Department of Radiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark
- 8 Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Denmark
- 9 Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark
- 10 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

submitted 12.4.2019

accepted after revision 16.7.2019

Bibliography

DOI <https://doi.org/10.1055/a-1027-6735> |
 Endoscopy International Open 2020; 08: E124–E132
 © Georg Thieme Verlag KG Stuttgart · New York
 eISSN 2196-9736

Corresponding author

Prof. Julie Gehl, Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Department of Clinical Oncology and Palliative Care, Zealand University Hospital,

Sygehusvej 10, 4000 Roskilde, Denmark

Fax: +46326994

kgeh@regionsjaelland.dk

ABSTRACT

Background and study aims Electrochemotherapy is an anticancer treatment that uses electric pulses to facilitate uptake of chemotherapeutic drugs in tumor cells and has proven to have a high local cytotoxic effect with minimal adverse events. Electrochemotherapy has mostly been used in treatment of cutaneous metastases but development of a new endoscopic electrode device has made treatment of colorectal tumors possible. This first-in-man multicenter phase I study investigated safety and efficacy of electrochemotherapy using endoscopic electroporation in patients with colorectal tumors.

Patients and methods Seven patients with colorectal tumors who were deemed ineligible for or had declined standard treatment were included. They were treated with bleomycin either intratumorally or intravenously and the electric pulses were delivered through the endoscopic electrode device. Safety and efficacy were assessed clinically and by scans immediately after treatment and adverse events were reported. Response was evaluated up to 6 months after treatment by scans (magnetic resonance imaging or computed tomography) and endoscopic examinations.

Results Seven patients aged 62 to 88 years with multiple comorbidities were included and had one or two treatments each. Post-treatment scans showed tumor responses in the treated areas and no damage to surrounding tissues. Only a few grade one adverse events were reported. Three patients had preoperative rectal bleeding, of which two reported cessation of bleeding and one reported decreased bleeding.

Conclusion This first-in-man study shows that electrochemotherapy for colorectal tumors using the endoscopic electrode device can induce local tumor response and is safe also for fragile elderly patients with comorbidities.

Introduction

Colorectal cancer is the third most commonly diagnosed cancer in both men and women worldwide with approximately 1.4 million new cases every year [1]. Standards of treatment include surgery, radiotherapy, and oncological treatment (chemotherapy and antineoplastic antibodies). Most new cases of colorectal cancers are in older patients. In 2014, 64% to 68% of new colorectal cases in the United States were men and women aged 65 years and older [2].

Electrochemotherapy is an emerging and effective treatment that utilizes the effect of electric pulses to increase uptake of chemotherapy in cancer cells. Short high-voltage pulses are delivered locally to the tumor, which transiently permeabilizes cell membranes, enabling otherwise non-permeant chemotherapeutic drugs to enter the cancer cells [3–5]. The most widely used chemotherapeutic drug for electrochemotherapy is bleomycin. Bleomycin is a large, hydrophilic and charged molecule without a specific cellular uptake mechanism, but intracellularly, it is highly cytotoxic because of its ability to create several single- and double-strand DNA breaks [6]. When electric pulses facilitate the uptake of bleomycin, the cytotoxic effect is enhanced by more than 300-fold [7–9].

Electrochemotherapy has mostly been used in treatment of cutaneous and subcutaneous tumors as these are easily accessible for electrodes. This has shown an objective response in approximately 85% for tumors 3 cm or less after only one treatment and regardless of histology [10–19]. Electrochemotherapy has also been shown to be an easily tolerated treatment, especially for elderly patients [20, 21].

Development of new electrodes has now made it possible to start investigations of electrochemotherapy to internal tumors as well [22–25]. A new endoscopic vacuum electrode device has been developed to treat gastrointestinal tumors with electric pulses [26]. This device has been tested in preclinical studies in porcine and canine models and has demonstrated that it is safe and resulted in complete regression of colorectal tumors in two out of two treated dogs with no relapse after 2 years [26].

This was a first-in-man clinical study using an endoscopic electrode device for electrochemotherapy on inoperable colorectal tumors. This article describes the experiences and results from the first seven treated patients.

Patients methods

Setting

This was an exploratory phase 1 multicenter study examining electrochemotherapy in seven patients with inoperable colorectal cancer using an endoscopic electrode device in combination with bleomycin. Endpoints were to investigate tumor regression and assess the safety of the treatment. Patients were recruited at Mercy University Hospital, Cork, Ireland, St Vincent's Hospital, Dublin and Copenhagen University Hospital Herlev and Gentofte, Denmark. The protocol was approved by the Irish Medicines Board and the Danish Medicines Agency,

the Regional Ethics Committees and the Danish Data Protection Agency. Clinicaltrials.gov identifier: NCT01172860.

Endpoints

Endpoints were to investigate tumor regression via magnetic resonance imaging (MRI) (if MR not possible then computed tomography [CT] or endoscopic images) at 3 and 6 months post the initial procedure and assess the safety of the treatment by reviewing adverse events (AEs) as they arose. Safety evaluation included report of tissue perforation, inflammatory response, electrode device issues and any AEs.

Patients

Eligible patients had a histologically verified colorectal tumor and were reviewed by a multidisciplinary team who found no further standard treatments available and considered enrolment in this study to be the most appropriate option. Patients could also be included if they refused to undergo offered standard treatment options. Other inclusion criteria were: age ≥ 18 years, WHO performance status ≤ 2 [27] or Karnofsky $> 60\%$ [28], treatment-free interval of at least 2 weeks (4 weeks if last treatment included bevacizumab), patients deemed capable of understanding the given information and written informed consent. Ineligibility criteria included non-correctable coagulation disorder, s-creatinine $> 150 \mu\text{mol/L}$ and with chrome-EDTA-clearance $< 40 \text{ mL/min}$, severe lung disease, highly inflamed colon tissue with ulceration and bleeding, implanted stent in colon, previously allergic reaction to bleomycin, previous treatment with bleomycin with a cumulative dose of $200,000 \text{ units/m}^2$, participation in another clinical trial, any other clinical condition or previous treatment that, in the investigators opinion, made the patient ineligible, and pregnancy or lactation in women (s-HCG mandatory). Women of childbearing potential and sexually active men had to use adequate contraception during and up to 6 months after last treatment.

Screening

When informed consent was signed, patients were screened with blood samples, chrome-EDTA clearance (only if s-creatinine was $> 150 \mu\text{mol/L}$), and endoscopic examination was performed. If screening met the inclusion criteria and an anesthetist assessed the patients eligible for anesthesia, the patients were included.

Bowel preparation

Bowel preparation was performed with either enema or Citrafleet and Toilax.

Anesthesia

Patients were anesthetized to alleviate discomfort from manipulation and pain from muscle contractions created by the electric pulses. They were sedated with propofol and fentanyl if not recommended otherwise by the anesthetist. To prevent lung toxicity from bleomycin, the fraction of inspired oxygen was limited to 30% during anesthesia as standard operating procedure [29].

Injection of chemotherapy

Bleomycin was administered intravenously (IV) or intratumorally (IT) depending on what was considered most suitable for the patient by the treating doctors. IV bleomycin was administered in fast drip; 15,000 IU/m² body surface (Denmark: bleomycin Baxter; Ireland: MaynePharma) diluted in 250 mL isotonic sodium chloride. Pulses were delivered, starting from 8 minutes after injection, according to ESOPE (European Standard Operating Procedure on Electrochemotherapy) [29, 30]. IT bleomycin was administered intratumorally; 1,000 IU/mL with dose of 250 IU/cm³ for tumors larger than 1 cm³, 500 IU for tumors smaller than 1 cm³ but larger than 0.5 cm³, and 1000 IU/cm³ for tumors smaller than 0.5 cm³, to compensate for loss to the circulation relative to injected volume. This was in accordance to ESOPE [29, 30].

Endoscopic electrode device (EndoVe), Cliniporator and pulses

The EndoVe device (700209, Mirai Medical, Galway, Ireland) is a single-use device developed to attach to a standard endoscope. The treatment head is a chamber (approximately 2.5 cm³) containing two plate electrodes (gold plated, 25-micron thick, on flexible polyimide L 20 mm W 8 mm) and connected to a vacuum system to draw the tumor tissue into the chamber allowing electric field application (► Fig. 1).

The device was connected to a square wave pulse generator (In Denmark: Cliniporator, type ref EPS01, IGEA, Carpi, Italy; In Ireland: Cliniporator, IGEA Carpi, Italy & ePORE, Mirai medical, Galway Ireland) which delivered eight pulses of 0.1 ms duration with a frequency of 5 kHz and an amplitude of 1 kV/cm (voltage to electrode distance ratio). A negative pressure between -100 to -760 mmHg was used to draw tissue into the chamber delivered by a surgical suction pump (HCPCS E0600, Atmos Medical, Germany).

Endoscopic procedure and administration of electric pulses

Before treatment, the tumor was inspected endoscopically and biopsies were collected from the intended treatment area. After injection of bleomycin, the electrode device was attached to the tip of the endoscope and placed on the tumor. Vacuum was applied to draw tumor tissue into the electrode chamber while electric pulses were delivered. Tumor area was treated by repeating positioning, vacuum, and pulsing until the treatment volume was covered. The treatment was performed by a specialist surgical endoscopist, and clinical experience was used to define treatment volume, assisted by preoperative scans and endoscopy.

Follow-up

If the patients were able, they had a follow-up endoscopy 6, 12, 18 and 24 weeks after initial treatment to evaluate change in tumor size and shape and to collect biopsies from the treated area for histological analysis. The patients were offered retreatment in case of remaining tumor tissue and if they were deemed suitable by the investigator. A maximum of two repeat treatments were performed in a minimum interval of 6 weeks (► Fig. 2).


Assessment of safety

Safety was evaluated on reported AEs.


Assessment of response

Methods for monitoring treatment efficacy included CT or MRI for tumor volume assessment and endoscopy visual assessment.

Imaging was performed to evaluate response at baseline, 4 weeks (only in Denmark), 12 weeks and 24 weeks after first treatment (► Fig. 2). In Denmark: CT scans were performed with IV contrast Iomeron 350 mg Iodine/mL. Slice thickness 3 mm, KVP 100, mA 426 FOV 31.4. MRI was performed as anatomic standard using T2 and diffusion sequences. The MRI pro-



► Fig. 1 a Illustration of the endoscopic vacuum electrode (EndoVe), an electrode developed to attach to a standard endoscope and vacuum system. b Illustration of the treatment head; a chamber approximately 2.5 cm³ containing two plate electrodes [34]. c Illustration of the EndoVe device in colon. The treatment head is placed on tumor tissue which is drawn by negative pressure into the electrode chamber allowing application of the electric field. Source: Cork Cancer Research Centre



protocol comprised T2 scans in three planes, sagittal, para-coronal (parallel to the axis along the length of the affected tissue) and transversal (perpendicular to the aforementioned axis and hence the para-coronal images). All three scans had TR/TE = 1946/120, flip angle (FA) = 90, an in-plane resolution of 0.5 mm × 0.5 mm and a slice thickness of 3 mm. The DWI scans were recorded with spin-echo acquisition, DWI-SE, to avoid the rather large susceptibility artifacts usually seen with the more common DWI-EPI approach, although this necessitates further repeats of the sequence to gather sufficient signal. Parameters for the DWI-SE were TR/TE = 9289/74, FA = 90, resolution of 1.8 mm × 2.0 mm, thickness 3 mm, SPIR fat-sat and five b-values 0, 50, 150, 750 and 1000. All scans were performed on a 1.5T Achieva clinical scanner (Philips Healthcare, Best, the Netherlands). To minimize intestinal peristalsis during MRI, patients had Buscopan 20 mg intramuscularly. All MRI and CT scans were evaluated by the same radiologist.

Statistics

This was an exploratory first-in-man trial and only descriptive statistics were used.

Results

The study was initiated at Cork Cancer Research Centre in Ireland but became affected by staff changes and for this reason, the protocol was extended to Copenhagen University Hospital Herlev and Gentofte, Denmark.

Patients

A total of seven patients were included and treated. Four patients were included at Mercy University Hospital, Cork, Ireland from March 2010 to December 2012 and three patients were included at Copenhagen University Hospital Herlev and Gentofte, Denmark from July 2015 to September 2015. Three men and four women aged 62 to 88 with WHO performance status from 1 to 2 and with diverse comorbidity as early Alzheimer's disease, diabetes, nephropathy, respiratory and cardiac disease (arrhythmia, implanted pacemaker, biological aortic valves, previous coronary artery bypass grafting and previous apoplexy) were included. Five patients had local disease (T1–4 N0 M0) and 2 patients had loco regional disease (T1–4 N1–2 M0). Five of seven patients had received treatment for their colorectal cancer before inclusion (► **Table 1**).

Treatment procedure

All patients were treated with IV bleomycin, and one patient in Ireland was treated with both IV and IT bleomycin infusion in same treatment due to exophytic component of the tumor. A median of 16 pulses (range 7–34 pulses) was applied in each treatment. Immediately as the pulses were applied the treated tumor tissue appeared ischemic. The cliniporator was set to deliver 1000 V, but in two cases the voltage was decreased, one to 900 V due to generator limitations (patient 6) and one to 650 V due to discomfort from the electrical pulses (patient 3). Median time from start of bleomycin infusion to last pulse was 48 minutes (range 18–80 min).

Four patients had retreatment and mean time between treatments was 51 days (range 43–57 days)(► **Table 2**).

Response evaluation

Response evaluation was not uniform due to different imaging and different follow-up and several patients had treatment in only part of the tumor, thus response and follow-up is reported separately for each patient.

Patient 1 (Ireland)

A 78-year-old man, diagnosed with bleeding rectal tumor. Baseline MRI scan identified a T3N0 rectal tumor estimated to 3.0 × 2.5 cm. He refused perineal resection, radiotherapy and chemotherapy. He underwent two treatments: At the initial treatment, difficulties were encountered with placement of the electrode device due to tumor location and approximately 50% of tumor surface area was treated. At second treatment,

► **Table 1** Demographics.

Patient	Country	Sex	Age	Performance status (WHO)	Tumor stage	Comorbidity	Previous treatment
1	Ireland	M	78	2	T3 N2 M0	None reported	None
2	Ireland	M	77	2	T4 N2 M0	Respiratory compromise	Chemotherapy FOLFOX × 4 cycles
3	Ireland	F	74	1	T3 N0 M0	Early Alzheimers	None
4	Ireland	F	62	1	T4 N0 M0	None reported	Insulin potentiation therapy
5	Denmark	F	85	2	T2 N0 M0	Cardiovascular disease (biological aortic valve, pacemaker, arrhythmia, previous apoplexy)	Radiotherapy 5 Gy × 3
6	Denmark	F	88	2	T2 N0 M0	Arrhythmia	Argon beam
7	Denmark	M	71	1	T1 N0 M0	Diabetes, chronic nephropathy Cardiovascular disease (biological aortic valve, pacemaker)	Radiotherapy 1.8 Gy × 25

FOLFOX, fluorouracil, leucovorin and oxaliplatin; Gy, Gray.

► **Table 2** Treatments.

Patient	Country	Treatment number	Bleomycin (IE)		Pulses (n)	Highest current (A)	Treated tumor surface	Treatment duration (min)	Comment to treatment	Treatment outcome
1	Ireland	1	31,500	IV	9	7	>50%	80		Partial response
		2	31,500	IV	12	11	~ 100%	18		Complete response
2	Ireland	1	20,000	IV	17	16	>25%	25		Partial response
		2	20,000	IV	31		~ 100%	39		Complete response
3	Ireland	1	15,000	IV	8	4	>75%	22	Voltage decreased to 650 V due to discomfort from muscular contractions.	Partial response
4	Ireland	1	25,000 5,000	IV IT	11	16	>25%	32		Partial response
5	Denmark	1	27,450	IV	34	13	>25%	62		Partial response
6	Denmark	1	27,000	IV	7	21	>50%	48	Voltage decreased to 900 V due to lack of capacity of the cliniporator.	Partial response
		2	27,000	IV	18	21	>75%	24	Voltage decreased to 900 V due to lack of capacity of the cliniporator.	Partial response
7	Denmark	1	30,000	IV	16	21	~ 100%	31		Complete response
		2	30,000	IV	15	21	>75%	49		

IV, intravenous; IT, intratumoral

the remaining portion of the tumor was successfully treated with a reported cessation of rectal bleeding and the follow-up endoscopy revealed a complete endoluminal response. After 6 months the MRI scan indicated potential for residual disease and a subsequent rectal bleed resulted in the patient agreeing to an abdominal perineal resection.

Patient 2 (Ireland)

A 77-year-old man diagnosed with a T4N2 colorectal tumor was deemed unfit for operation and general anesthesia due to respiratory compromise and was previously treated with chemotherapy. He underwent two treatments. The initial treatment was only partially possible due to an obstructive component of the tumor, however, an estimated 90% reduction endoluminally was observed endoscopically and allowed for complete treatment at the second electrochemotherapy session. Response was only evaluated endoscopically. Post-treatment the patient reported excellent quality-of-life improvements with cessation of rectal bleeding and elimination of pressure and pain in the bladder. He succumbed to an unrelated disease 5 months after the initial procedure.

Patient 3 (Ireland)

A 77-year-old woman with early Alzheimer's disease (consent made by legal guardian), diagnosed with a T3N0 rectal tumor was deemed unsuitable for the standard of care (operation, chemotherapy and radiotherapy). She underwent one treatment that was performed under light sedation and was found to be distressing for the patient. Consequently, the applied voltage was reduced to 650 V to minimize discomfort from the muscular contractions associated with the procedure. Re-


sponse was only evaluated endoscopically and partial response was observed at 12 weeks follow-up. She was deemed unsuitable for a second treatment.

Patient 4 (Ireland)


A 58-year-old woman diagnosed with a T4 anorectal tumor. At baseline MRI, tumor was estimated to 5.4×4.7×7.9 cm and with a large exophytic component. She underwent one treatment. The exophytic component was successfully treated along with a portion of the anorectal component. Unfortunately, endoscopic follow-up and treatment was not feasible due to the hardened and compact nature of the rectal component of the tumor. The patient underwent CyberKnife radiotherapy on the untreated rectal component 3 months after electrochemotherapy. Follow-up scan 3 years post-treatment indicated complete response and the patient has regained her original weight and reports excellent quality of life.

Patient 5 (Denmark)

An 85-year-old woman was diagnosed with a bleeding rectal tumor causing need of several blood transfusions. She had severe cardiovascular disease and was ineligible for surgery or chemotherapy. She underwent palliative irradiation (5Gy×3) but bleeding relapsed. At baseline CT scan, the tumor was estimated to be 3.6×5.6×5.3 cm (MRI deemed ineligible due to pacemaker). She underwent one treatment. Due to the large tumor only 25% to 50% of tumor surface area was treated. At 1-month follow-up the CT scan showed regression in the treated area with estimated tumor size of 1.5×1.2×2 cm (► Fig. 3) and bleeding had decreased markedly. Retreatment was planned but cancelled twice due to other medical diseases. Five months



► **Fig. 3** Pre and post treatment CT scans from patient no. 5. CT evaluation from patient no. 5 treated at Herlev hospital, University of Copenhagen, Denmark. The patient only had one treatment. Baseline: Shows a rectal tumor, mainly on the posterior wall with maximum measurements of 3.6×5.9 cm and a craniocaudal extension of 5.3 cm. Treatment day: Performed a few hours after the procedure and shows no change in tumor volume but massive edema of the treated area. There is no free fluid, no sign of perforation and surrounding intestinal loops appear unaffected. One-month follow-up: Shows decreasing tumor 1.5×3.2 cm and craniocaudal extension 4.3 cm. There is still edema of the mucosa. Surrounding intestinal loops still unaffected. Five-month follow-up: Shows marked increase of tumor volume with mechanical obstruction of colon.



► **Fig. 4** Pre- and post-MRI from patient no. 6. MR evaluation from patient no. 6 treated at Herlev hospital, Denmark. The patient had two treatments. Baseline: MRI shows a circumscribed rectum tumor, thickest part 1.5 cm. Treatment day: MRI a few hours after first treatment. Only the right lateral wall was treated. The MRI shows edema in treated area. 1 month after treatment: One-month follow-up after initial treatment MRI shows decrease of tumor in the treated area. Three months after treatment: Two months after initial treatment, the patient was retreated to cover tumor in the left lateral wall. The MRI is 1 month after the second treatment and 3 months after the first treatment. The scan shows a decrease in the newly treated area but a progression in the right lateral wall.


after treatment, tumor progressed and a rectal stent was implanted.

Patient 6 (Denmark)

An 87-year-old woman was diagnosed with a T2N0 rectal tumor. She was assessed ineligible for surgery and chemotherapy due to poor performance status and refused radiotherapy. She was treated with repetitive argon beaming but tumor progressed. Baseline MRI scan showed a circumferential tumor estimated to be 1.5 cm thick. She underwent two treatments: At the initial treatment, the patient appeared with arrhythmia which resulted in non-sufficient anesthesia/sedation and treatment was discontinued after treatment of 50% to 75% of tumor surface area. In addition, voltage was decreased to 900 V due to generator limit. At 1-month follow-up, MRI showed disappearance of tumor tissue equivalent to treatment area (► **Fig. 4**). A second treatment was performed, again with successful regression of treatment area, but tumor progressed profound the treatment area. Five months after the first treatment, she was referred for radiation therapy.

Patient 7 (Denmark)

A 71-year-old man with diabetes, chronic nephropathy, and severe cardiovascular disease had relapse of rectal cancer after radiotherapy (1.8 Gy × 27). Due to comorbidity he was deemed ineligible for chemotherapy and he refused surgery. Baseline CT scan showed a small tumor on the posterior wall of the sigmoid colon measuring 2.0 × 1.0 × 1.2 cm (MRI deemed not possible due to pacemaker). He underwent two treatments. At the initial treatment ~100% of tumor surface area was treated (► **Fig. 5**). At 1-month follow-up, CT scan showed disappearance of the tumor. At 7 weeks follow-up, endoscopy showed tumor tissue at the lateral margins and he was retreated. The tumor relapsed after 5 months and the patient then agreed to undergo surgery.



► **Fig. 5** Pictures from endoscopic examination before and after treatment. Endoscopic pictures from patient no. 7 treated at Herlev hospital, Denmark. Baseline picture shows a rectal tumor estimated 3 × 2 cm. Six weeks after treatment there is a necrotic tumor decreased in size and surrounded by fibrotic tissue.

Safety

Overall, no severe AEs were reported. In the Irish cohort, two patients had temperature rise 24 hours post-treatment and one had rectal bleeding 4 weeks post-treatment. In the Danish cohort, none of the patients reported post-treatment pain 6, 12 and 24 hours after treatment. Three patients had altered bowel movements up to 2 weeks after treatment and minor problems with both loose and hard stool were reported. One patient reported mild nausea lasting 2 days after treatment and one patient reported headaches and pain in joints the day after treatment.

No device issues were reported regarding concerns about safety. In the three Danish patients who had MRI or CT scans 1 to 2 hours after treatment, the scans showed edema in the treated area, but no AEs, bleeding or perforation. Three patients had preoperative rectal bleeding, whereas two reported cessation of bleeding (2 Irish patients) and one markedly decrease of bleeding post treatment (Danish patient).

Discussion

In this first human study, seven patients with colorectal cancer were successfully treated with electrochemotherapy delivered by an endoscopic electrode device, resulting in local tumor responses and only limited AEs.

The patients seen in this study were elderly fragile patients with multiple comorbidities and were deemed ineligible for surgery or other standard treatments. Despite this, tumor response was seen after only one treatment in all patients and the procedure was well tolerated. The procedure was performed as an outpatient procedure, so the patients went home a few hours after the treatment and could maintain everyday life.

Electrochemotherapy is widely used for cutaneous metastases [10–18] and high response rates have consistently been reported across tumor histologies. This finding may be explained by the local enhanced effect of bleomycin of over 300-fold [7–9] making it possible to achieve tumor response even after a single treatment. In this study, the effect of treatment was seen during the procedure as tumor vessels in the treated area stopped bleeding and the tumor tissue attained a pale or cyanotic color.

Electrochemotherapy is known to have an antivasular effect with reflexive vascular constriction followed by destruction of tumor vessels and has also shown immediately and long-term cessation of bleeding in treatment of cutaneous metastases [31–33]. This is in line with the finding from this study that three patients with preoperative rectal bleeding reported marked reduction or complete cessation of bleeding. Bleeding persisted, although at a markedly reduced level, in one patient, and she had treatment of only 25% to 50% of the tumor surface area. This finding highlights the potential use of electrochemotherapy as a palliative treatment for colorectal cancer, as rectal bleeding is a frequent symptom in this patient group.

Tumor reduction was only seen in the tumor tissue covered by the electric field. In several patients it was not possible to

reach the tumor margins either because of limited visibility due to the electrode device or because of tumor thickness. One patient had relapse in the treated tissue and three patients had relapse or progression in the untreated tumor tissue but none had visual progression in the treated tissue (CT, MR or endoscopic).

No safety issues were reported with the electrode device, although the voltage was decreased in two patients. One patient was only lightly sedated and experienced discomfort from the muscular contractions associated with the procedure; fully sedated patients did not report any discomfort. In the second case, voltage was reduced due to generator limitation. In this study we used a generator developed for treatment of cutaneous electrodes, the first version of the cliniporator (cliniporator EPS01), and this may explain why the generator was working close to its limit.

This was the first phase 1 clinical study to investigate the feasibility and safety of endoscopically delivered electrochemotherapy. The effect was observed endoscopically after a very short interval and had a palliative effect with immediate cessation of bleeding and reduction of intraluminal tumor masses as verified by respectively MR and CT scans.

A similar system with an endoscopic electrode device has been used in a phase 1 study to treating patients with esophageal cancer successfully with electrochemotherapy [34]. Also here the treatment was well tolerated and tumor response was visualized in five of six patients.

Standard therapeutic options for unresectable colorectal cancer include chemotherapy, radiotherapy, laser ablation or stenting. Electrochemotherapy adds an additional treatment option that is performed once or only a few times and can be used in refractory cases or where symptom palliation is needed, e.g. during other types of systemic chemotherapy regimens.

Interestingly, novel preclinical data indicate an immunostimulatory effect of electrochemotherapy in a murine colorectal cancer model [35]. Further studies may clarify if electrochemotherapy can be used as part of an immunostimulatory procedure giving rise to local tumor cell kill as well as release of tumor antigens.

Conclusion

Electrochemotherapy is a simple and safe treatment and has the potential to be a palliative option for patients with colorectal tumors deemed ineligible for standard treatments. It could also be advantageous in combination with standard treatments to perform tumor debulking or to stop symptomatic rectal bleeding.

Competing interests

Dr. Soden reports a conflict of interest regarding a patent on the EndoVe electrode as well as owner interests in Mirai Medical.

References

- [1] Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; 65: 87–108
- [2] Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. *CA Cancer J Clin* 2014; 64: 104–117
- [3] Mir LM, Orlowski S. Mechanisms of electrochemotherapy. *Adv Drug Deliv Rev* 1999; 35: 107–118
- [4] Mir LM. Bases and rationale of the electrochemotherapy. *EJC Suppl* 2006; 4: 38–44
- [5] Yarmush ML, Golberg A, Sersa G et al. Electroporation-based technologies for medicine: principles, applications, and challenges. *Annu Rev Biomed Eng* 2014; 16: 295–320
- [6] Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. *Cancer Treat Rev* 2003; 29: 371–387
- [7] Orlowski S, Belehradek J Jr., Paoletti C et al. Transient electroporation of cells in culture. Increase of the cytotoxicity of anticancer drugs. *Biochem Pharmacol* 1988; 37: 4727–4733
- [8] Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electroporation: an improved method for screening drugs. *Anticancer Drugs* 1998; 9: 319–325
- [9] Jaroszeski MJ, Dang V, Pottinger C et al. Toxicity of anticancer agents mediated by electroporation in vitro. *Anticancer Drugs* 2000; 11: 201–208
- [10] Marty M, Sersa G, Garbay JR et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. *EJC Suppl* 2006; 4: 3–13
- [11] Matthiessen LW, Chalmers RL, Sainsbury DC et al. Management of cutaneous metastases using electrochemotherapy. *Acta Oncol* 2011; 50: 621–629
- [12] Matthiessen LW, Johannesen HH, Hendel HW et al. Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial. *Acta Oncol* 2012; 51: 713–721
- [13] Belehradek M, Domenge C, Luboinski B et al. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. *Cancer* 1993; 72: 3694–3700
- [14] Campana LG, Mocellin S, Basso M et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. *Ann Surg Oncol* 2009; 16: 191–199
- [15] Curatolo P, Quagliano P, Marengo F et al. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. *Ann Surg Oncol* 2012; 19: 192–198
- [16] Heller R, Jaroszeski MJ, Reintgen DS et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. *Cancer* 1998; 83: 148–157
- [17] Kis E, Olah J, Ocsai H et al. Electrochemotherapy of cutaneous metastases of melanoma—a case series study and systematic review of the evidence. *Dermatol Surg* 2011; 37: 816–824
- [18] Quagliano P, Mortera C, Osella-Abate S et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. *Ann Surg Oncol* 2008; 15: 2215–2222
- [19] Clover AJP, Bertino G, Curatolo P et al. Electrochemotherapy in the treatment of cutaneous malignancy; outcomes and subgroup analysis from the cumulative results from the pan-European InspECT Database for 1478 lesions in 691 patients (2008-2018). Budapest: ESSO38 (European Society of Surgical Oncology, 38th Congress); 2018
- [20] Matthiessen LW, Chalmers RL, Sainsbury DC et al. Management of cutaneous metastases using electrochemotherapy. *Acta Oncol* 2011; 50: 621–629
- [21] Benevento R, Santoriello A, Perna G et al. Electrochemotherapy of cutaneous metastases from breast cancer in elderly patients: a preliminary report. *BMC Surg* 2012; 12: (Suppl. 01): S6
- [22] Linnert M, Iversen HK, Gehl J. Multiple brain metastases – current management and perspectives for treatment with electrochemotherapy. *Radiol Oncol* 2012; 46: 271–278
- [23] Edhemovic I, Gadzije EM, Breclj E et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. *Technol Cancer Res Treat* 2011; 10: 475–485
- [24] Campana LG, Edhemovic I, Soden D et al. Electrochemotherapy - Emerging applications technical advances, new indications, combined approaches, and multi-institutional collaboration. *Eur J Surg Oncol* 2019; 45: 92–102
- [25] Miklavcic D, Sersa G, Breclj E et al. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. *Med Biol Eng Comput* 2012; 50: 1213–1225
- [26] Forde PF, Sadacharam M, Bourke MG et al. Preclinical evaluation of an endoscopic electroporation system. *Endoscopy* 2016; 48: 477–483
- [27] Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982; 5: 649–655
- [28] Karnofsky DA, Abelmann WH, Craver LF et al. The use of the nitrogen mustards in the palliative treatment of carcinoma – with particular reference to bronchogenic carcinoma. *Cancer* 1948; 1: 634–656
- [29] Gehl J, Sersa G, Matthiessen LW et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. *Acta Oncol* 2018; 57: 874–882
- [30] Mir LM, Gehl J, Sersa G et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator™ by means of invasive or non-invasive electrodes. *EJC Suppl* 2006; 4: 14–25
- [31] Markelc B, Sersa G, Cemazar M. Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels. *PLoS One* 2013; 8: e59557
- [32] Sersa G, Cemazar M, Miklavcic D et al. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. *Anticancer Res* 1999; 19: 4017–4022
- [33] Jarm T, Cemazar M, Miklavcic D et al. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. *Expert Rev Anticancer Ther* 2010; 10: 729–746
- [34] Egeland C, Baeksgaard L, Johannesen HH et al. Endoscopic electrochemotherapy for esophageal cancer - a phase I clinical study. *Endosc Int Open* 2018; 6: E727–E734
- [35] Falk H, Forde PF, Bay ML et al. Calcium electroporation induces tumor eradication, long-lasting immunity and cytokine responses in the CT26 colon cancer mouse model. *Oncoimmunology* 2017; 6: e1301332